Copyright
©The Author(s) 2005.
World J Gastroenterol. Aug 28, 2005; 11(32): 4939-4946
Published online Aug 28, 2005. doi: 10.3748/wjg.v11.i32.4939
Published online Aug 28, 2005. doi: 10.3748/wjg.v11.i32.4939
Table 1 Sequences of primers and TaqMan® probe for MUC1 and MUC5AC apomucins
Mucin | Primer or probe | Sequence | Product size |
MUC1 | Forward | GCTATGTGCCCCCTAGCAGTAC | 73 |
Reverse | AGGCTGCTGCCACCGTTA | ||
Probe | TCGTAGCCCCTATGAGAAGGTTTCTGCAG | ||
MUC5AC | Forward | CCCCAACATCAGGAACAGCTT | 147 |
Reverse | GAGTAGTAGGTTCCCGGCTTCA | ||
Probe | AGCGTGGAGAATGAGAAGTATGCTCAGCAC |
Table 2 Expression of MUC1 and MUC5AC apomucins, demographic data, cancer histopathology, and clinical staging of ICC patients
Variables | n (87) | % | |
Age (yr) | ≤56 | 42 | 48.3 |
>56 | 45 | 51.7 | |
Sex | Male | 59 | 67.8 |
Female | 28 | 32.2 | |
Tumor staging | I–III | 14 | 16.1 |
IVA | 16 | 18.4 | |
IVB | 57 | 65.5 | |
Histological grading | Papillary | 20 | 22.9 |
Well-differentiated | 26 | 29.8 | |
Moderately differentiated | 11 | 12.6 | |
Poorly differentiated | 20 | 22.9 | |
Unclassified | 10 | 11.5 | |
Tumor size | ≤5 cm | 24 | 27.6 |
>5 cm | 63 | 72.4 | |
Vascular invasion | No | 30 | 34.5 |
Yes | 57 | 65.5 | |
Neural invasion | No | 46 | 52.9 |
Yes | 41 | 47.1 | |
Lymphatic invasion | No | 23 | 26.4 |
Yes | 64 | 73.6 | |
Mucin expression | MUC1 and MUC5AC | 52 | 59.7 |
MUC1 only | 15 | 17.3 | |
MUC5AC only | 12 | 13.8 | |
None | 8 | 9.2 | |
MUC1 expression | Low (0, 1+) | 53 | 60.9 |
High (2+, 3+) | 34 | 39.1 | |
MUC5AC expression | Low (0, 1+) | 41 | 47.1 |
High (2+, 3+) | 46 | 52.8 |
Table 3 Expressions of MUC1 and MUC5AC apomucins in ICC in relation to patients’ cancer histopathology and clinical staging
Variables | MUC1 | P | MUC5AC | P | ||
Low | High | Low | High | |||
Age (yr) | 53 | 34 | 0.894 | 41 | 46 | 0.065 |
≤56 | 26 | 17 | 15 | 27 | ||
>56 | 27 | 17 | 26 | 19 | ||
Gender | 53 | 34 | 0.698 | 41 | 46 | 0.058 |
Male | 34 | 24 | 32 | 26 | ||
Female | 19 | 10 | 9 | 20 | ||
Histological grading | 43 | 24 | 0.575 | 34 | 33 | 0.095 |
Papillary | 13 | 7 | 11 | 9 | ||
Well-diff. | 18 | 8 | 9 | 17 | ||
Moderately diff. | 5 | 6 | 6 | 5 | ||
Poorly diff. | 7 | 3 | 8 | 2 | ||
Tumor size | 51 | 31 | 0.964 | 38 | 44 | 0.502 |
≤5 cm | 15 | 9 | 13 | 11 | ||
>5 cm | 36 | 22 | 25 | 33 | ||
Staging | 50 | 32 | 0.94 | 39 | 43 | 0.008 |
I-III | 8 | 5 | 6 | 7 | ||
IVA | 6 | 5 | 10 | 1 | ||
IVB | 36 | 22 | 23 | 35 | ||
Vascular invasion | 53 | 34 | <0.001 | 41 | 46 | 0.284 |
No | 27 | 2 | 17 | 14 | ||
Yes | 26 | 30 | 24 | 32 | ||
Lymphatic invasion | 53 | 34 | 0.995 | 41 | 46 | 0.124 |
No | 14 | 9 | 14 | 9 | ||
Yes | 39 | 25 | 27 | 37 | ||
Neural invasion | 53 | 34 | 0.384 | 41 | 46 | 0.022 |
No | 30 | 16 | 27 | 19 | ||
Yes | 23 | 18 | 14 | 24 |
Table 4 Significant prognostic factors for disease-free survival by multivariate analysis
Variables | Crude HR (95%CI) | Adjusted HR (95%CI) | P |
MUC1 expression | 0.026 | ||
Low | 1 | 1 | |
High | 2.59 (1.54-4.35) | 2.19 (1.11-4.32) | |
MUC5AC expression | 0.059 | ||
Low | 1 | 1 | |
High | 1.36 (0.83-2.24) | 2.06 (0.96-4.41) | |
Age (yr) | 0.571 | ||
≤56 | 1 | 1 | |
>56 | 0.86 (0.53-1.42) | 1.19 (0.65-2.17) | |
Gender | 0.128 | ||
Male | 1 | 1 | |
Female | 0.63 (0.37-1.09) | 0.60 (0.31-1.18) | |
Histological grading | <0.050 | ||
Papillary | 1 | 1 | |
Well-differentiated | 1.86 (0.91-3.83) | 1.92 (0.82-4.49) | |
Moderately differentiated | 3.65 (1.59-8.41) | 3.00 (1.10-8.20) | |
Poorly differentiated | 1.78 (0.70-4.53) | 3.02 (0.97-9.41) | |
Staging | <0.050 | ||
I–III | 1 | 1 | |
IVA | 2.49 (0.81-7.62) | 5.10 (1.27-20.43) | |
IVB | 3.57 (1.41-9.00) | 3.93 (1.47-10.51) |
- Citation: Boonla C, Sripa B, Thuwajit P, Cha-On U, Puapairoj A, Miwa M, Wongkham S. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol 2005; 11(32): 4939-4946
- URL: https://www.wjgnet.com/1007-9327/full/v11/i32/4939.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i32.4939